Merck & Co., Inc. Reports Earnings for Fourth Quarter and Full Year of 2024

Merck & Co., Inc., a leading pharmaceutical company, filed its Form 8-K report with the Securities and Exchange Commission on February 4, 2025. In this report, Merck disclosed its financial results for the fourth quarter and year ended 2024, providing insights into its performance during this period.

The company’s consolidated statement of operations indicated a 7% increase in sales, with a total of $64,168 million for the full year 2024 compared to $60,115 million for the previous year. The net income attributable to Merck & Co., Inc. for the same period was $17,117 million.

A breakdown of key product sales for the fourth quarter of 2024 showed positive performance in certain pharmaceutical segments. Keytruda, one of Merck’s flagship products, saw a 19% increase in sales, reaching $7,836 million. Other notable products such as Gardasil/Gardasil 9 and ProQuad/M-M-R II/Varivax showcased mixed results in the vaccine category.

In line with financial reporting regulations, Merck included non-GAAP reconciliation details in the filing to provide investors with a clear understanding of the company’s underlying business performance. The company emphasized the significance of these non-GAAP measures in assessing its performance and strategic planning.

Merck’s full-year results reflected a holistic view of its operational performance, outlining key achievements and challenges across various product lines and geographical segments. The company continues to focus on innovation and market expansion to drive growth and value for its shareholders.

The filing also included additional details related to the impact of acquisition and divestiture-related costs, restructuring expenses, and other items affecting the reported financial figures. These disclosures aimed to provide transparency and enhance stakeholders’ understanding of the company’s financial position.

Merck & Co., Inc. remains committed to delivering innovative healthcare solutions and sustaining its position as a prominent player in the pharmaceutical industry. The company’s financial disclosures underscore its dedication to transparency and accountability in reporting its performance to investors and regulatory authorities.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Merck & Co., Inc.’s 8K filing here.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.